Key result
Ticagrelor shows no benefit over clopidogrel after small-diameter stenting in type 2 diabetes.
Why the study?
Does ticagrelor reduce composite MACE compared to clopidogrel in T2DM patients after small-diameter stent implantation?
Cohort (n=332)
Open-label
No
Does ticagrelor reduce composite MACE compared to clopidogrel in T2DM patients after small-diameter stent implantation?
In T2DM patients receiving small-diameter stents, ticagrelor did not reduce 1-year MACE compared to clopidogrel but significantly increased bleeding risk.
Answers are grounded in this paper and cite their sources.
Does not support ticagrelor over clopidogrel in T2DM patients with small stents; leaves open need for RCTs to assess bleeding risk.
BACKGROUND: Type 2 diabetes mellitus (T2DM) patients with small-diameter stents (SDS), that are equal to or less than 2.5 mm in diameter, face increased risks of restenosis and complications. This study aimed to evaluate the 1-year follow-up to assess the rate of major adverse cardiac events (MACE) and bleeding risk between ticagrelor and clopidogrel in T2DM patients after SDS implantation. METHODS: The study was a single-center, prospective controlled registry trial, which included 332 T2DM patients who underwent percutaneous coronary intervention with SDS implantation. Follow-up was conducted for 1 year. RESULTS: Following propensity score matching, the 1-year analysis revealed no significant difference in the risk of the composite MACE between clopidogrel and ticagrelor groups (P = .295). Male gender, history of ischemic heart disease, ejection fraction (EF), coronary lesion type, and chronic kidney disease (CKD) were identified as potential predictors for the composite endpoint. In a subanalysis of CKD patients, the 12-month rates of composites of cardiac death (CD), myocardial infarction (MI), stroke, and target vessel revascularization (TVR) were lower in the ticagrelor group than in the clopidogrel group (P = .024). However, the ticagrelor group was associated with a higher rate of bleeding compared to the clopidogrel group (20% vs. 9%) (P = .041). CONCLUSION: Our study demonstrated that ticagrelor did not show improvement in the composite of CD, MI, stroke, TVR, or the risk of bleeding events defined by the BARC criteria in patients with T2DM and SDS compared with clopidogrel emphasizing the importance of individualized treatment decisions based on patient characteristics. However, the results may not be representative of the entire population.
No takes yet. Share an insight, caveat, or question.
Alaa Solaiman Algazzar (2025) conducted a cohort in Type 2 diabetes mellitus with small-diameter stents (n=332). Ticagrelor vs. Clopidogrel was evaluated on Composite of cardiac death, myocardial infarction, stroke, and target vessel revascularization at 1 year (HR 1.39, 95% CI 0.751-2.573, p=0.295). Ticagrelor did not significantly reduce the 1-year risk of the composite of cardiac death, myocardial infarction, stroke, and target vessel revascularization compared to clopidogrel in patients with type 2 diabetes after small-diameter stent implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: